Several transgenic mouse tumor models were utilized to explore how speci®c genetic alterations aect the tumor cell response to chemotherapeutic agents in vivo. Speci®cally, MMTV-ras transgenic mice were interbred to p53 knock-out mice to create a model for assessing the role of p53 in chemotherapeutic responses. In addition, MMTV-ras tumors were compared to MMTV-myc and MMTV-ras/myc tumors. Mice of each genotype reproducibly develop mammary and/or salivary tumors, but tumor growth dynamics vary considerably between genotypes. MMTV-ras/p53 7/7 tumors exhibit higher S phase fractions than MMTV-ras/p53 +/+ tumors, although both tumor types display very low apoptosis levels. In contrast, MMTV-myc tumors exhibit both high S phase fractions and spontaneous apoptosis levels. Tumor-bearing mice of each genotype were treated with either doxorubicin or paclitaxel, and eects on overall tumor growth, cell cycle distribution and apoptosis were evaluated. Surprisingly, neither agent eciently induced apoptosis in any of the tumor models, including those with wildtype p53. Rather, tumor responses were mediated primarily by changes in cell cycle distribution. However, the spontaneous apoptosis levels did serve as a predictor of tumor growth response, in that only those tumors with high pretreatment apoptosis levels underwent signi®cant regression following treatment with either agent.
Introduction
Activation of cell cycle checkpoints and induction of apoptosis are the predominant cellular responses to diverse types of damage caused by a variety of chemotherapeutic agents (Darzynkiewicz, 1994; Fisher, 1994; Kerr et al., 1994) . Therefore, the integrity of pathways mediating these responses is critical for successful anticancer treatment. In particular, numerous studies have indicated that tumor response to chemotherapy is largely a function of the successful induction of apoptosis (Fisher, 1994; Kerr et al., 1994) . Therefore, a thorough understanding of the role of these pathways in mediating drug response should facilitate the development of more eective treatments for cancer.
One of the key genes known to mediate the cellular response to genotoxic stress is the p53 tumor suppressor gene. p53 is the gene most frequently found to be mutated in human tumors (Hollstein et al., 1991) , and its inactivation has been correlated with impaired response to a number of chemotherapeutic agents, particularly those that function by inducing DNA damage (Fan et al., 1994; Lowe et al., 1993; Weinstein et al., 1997) . In response to DNA damage or a variety of other cellular insults, p53 becomes activated and subsequently promotes either cell cycle arrest or apoptosis (Yonish-Rouach, 1996) . Although the factors in¯uencing the decision between these two responses are still being actively investigated, it has been demonstrated that at least in some cellular contexts, the presence of speci®c growth factors or the activation of particular cellular signaling pathways in¯uences this decision (Canman et al., 1995; Polyak et al., 1996) .
In addition, activation of various oncogenes has been shown to aect the ability of cells to invoke both cell cycle checkpoints and the apoptotic cell death program (El-Deiry, 1997) . Most of the known oncogenes were originally identi®ed based on their activity as positive growth regulators that stimulate entry and progression through the cell cycle. However, many oncogenes also either positively or negatively regulate initiation of the apoptotic cell death program. For example, expression of c-myc sensitizes cells to a variety of apoptotic stimuli, including growth factor deprivation, DNA damaging agents or tumor necrosis factor (Evan et al., 1992; Klefstrom et al., 1997; Lotem and Sachs, 1993) . In contrast, activated ras promotes increased resistance to apoptotic stimuli in most contexts (Arends et al., 1993; Hundley et al., 1997a; Kaumann-Zeh et al., 1997; Lin et al., 1995; Nooter et al., 1995) . Therefore, oncogene expression may dierentially aect tumor cell responses to anticancer treatment through in¯uences on both cell cycle and apoptotic pathways.
During the process of tumorigenesis, cells acquire multiple genetic alterations, including both tumor suppressor gene inactivation and oncogene activation. It is presumably the unique combination of mutations present within any individual tumor that ultimately dictates its phenotype, including sensitivity to chemotherapeutic treatment. Therefore, it is important to determine how each of these alterations, individually and in combination with other alterations, impacts upon the ability of tumor cells to respond to agents with dierent mechanisms of action. Considerable progress has been made in correlating speci®c genetic alterations with patterns of chemotherapeutic drug sensitivity in vitro (Weinstein et al., 1997) . However, in vitro model systems are highly contrived with regard to a number of biological characteristics that could potentially aect drug sensitivity, such as substrate attachment, growth factor availability, and the absence of stromal cells. Furthermore, it has recently been demonstrated that chemosensitivity results obtained from in vitro studies are not necessarily predictive of results obtained in vivo (Waldman et al., 1997) . Thus, it is important to extend the knowledge gained from in vitro settings to in vivo models that more closely mimic the cellular environment and tumor evolution processes encountered in human tumors. Genetically engineered mice harboring activated oncogenes and/or inactivated tumor suppressor genes provide excellent tumor model systems that allow for correlations between speci®c genetic alterations and a variety of tumor properties.
We have utilized transgenic mice expressing combinations of either the activated v-Ha-ras or c-myc oncogenes, as well as mice de®cient for p53, to assess how these speci®c genetic lesions impact upon the ability of tumors to respond to two dierent chemotherapeutic agents, doxorubicin (Adriamycin) or paclitaxel (Taxol). Tumor response was evaluated by assessing changes in overall tumor growth rates, cell cycle pro®les, and levels of apoptosis. In each of the mouse tumor models evaluated, both doxorubicin and paclitaxel aected cell cycle distribution to a greater extent than apoptosis. However, pretreatment apoptosis levels did loosely correlate with the ability of tumors to regress in response to treatment. These studies suggest that tumors possessing high spontaneous apoptosis levels may regress in response to chemotherapy, even in the absence of a further induction of apoptosis, if tumor cell proliferation can be slowed. However, tumors possessing low pretreatment apoptosis levels are impaired in their ability to undergo chemotherapy-induced regression, unless a signi®cant induction of apoptosis can be achieved.
Results
Salivary tumor growth response to doxorubicin and paclitaxel in MMTV-ras/p53 +/+ and MMTV-ras/p53 7/7 mice p53 status has been shown to be a critical determinant of the ability of tumors to respond to a variety of chemotherapeutic agents, particularly those that induce DNA damage (Lowe et al., 1993; Weinstein et al., 1997) . However, it is less clearly involved in mediating tumor response to agents that do not cause DNA damage (Lanni et al., 1997; Shao et al., 1995; Wahl et al., 1996; Weinstein et al., 1997) . In order to evaluate the importance of p53 status in tumor response to dierent classes of agents in an in vivo tumor model system, we interbred MMTV-Haras transgenic mice (Sinn et al., 1987) with p53 knock-out mice (Donehower et al., 1992) to generate ras-driven mammary or salivary tumors that either possess or lack p53 function. We have previously demonstrated that p53-de®cient MMTV-ras mice develop primarily salivary tumors, due to a greater acceleration of salivary than mammary tumors in the MMTV-ras/p53 7/7 mice as compared to MMTV-ras/ p53 +/+ mice (Hundley et al., 1997b) . Therefore, only salivary tumor-bearing mice were included in these studies. The chemotherapeutic agents selected were doxorubicin (Adriamycin), which functions at least in part by inhibiting topoisomerase II, resulting in DNA double-strand breaks (Chabner, 1993) , and paclitaxel (Taxol), which perturbs microtubule dynamics and blocks mitosis, but does not induce DNA damage (Rowinsky and Donehower, 1995) . Doxorubicin has previously been shown in a number of models to function in a p53-dependent manner to induce tumor cell apoptosis (Lowe et al., 1993; Weinstein et al., 1997) . In contrast, most studies indicate that tumor response to paclitaxel is largely p53-independent (Weinstein et al., 1997) . Salivary tumor-bearing MMTV-ras/p53 +/+ and MMTV-ras/p53 7/7 mice were treated with either doxorubicin or paclitaxel for nine consecutive days, or were untreated, and tumor growth was monitored by daily caliper measurements. Untreated salivary tumors from MMTV-ras/ p53
mice displayed an increased growth rate compared to untreated salivary tumors from MMTV-ras/p53 +/+ mice, as previously described (Hundley et al., 1997b) (Figure 1a,d) . Further, the p53-de®cient tumors were markedly impaired in their response to doxorubicin (Figure 1b,e) . While MMTVras/p53 +/+ tumors underwent an immediate and complete tumor growth arrest, tumors from MMTV-ras/p53 7/7 mice initially continued growing at a rate comparable to the pretreatment rate, and only after several days of treatment began to exhibit growth arrest. In contrast to these results with doxorubicin, tumors of both genotypes exhibited immediate growth arrest in response to paclitaxel, although only the p53-wildtype tumors displayed signi®cant regression (Figure 1c ,f).
Apoptotic response of MMTV-ras/p53
+/+ and MMTV-ras/p53 7/7 salivary tumors to doxorubicin and paclitaxel Because of the well-documented role of p53 in mediating apoptosis in response to doxorubicin (Lowe et al., 1993; Weinstein et al., 1997) , it was of interest to determine whether dierences in the induction of apoptosis accounted for the dierential response of MMTV-ras/p53 +/+ and MMTV-ras/p53
tumors to doxorubicin. The pretreatment apoptosis levels were identical in MMTV-ras/p53
+/+ and MMTV-ras/p53 7/7 tumors, and were consistently low ( Figure 2 ). To assess changes in apoptosis following treatment, mice of both genotypes were sacri®ced 48 h after a single treatment with doxorubicin, and tumor apoptosis levels were evaluated using the TUNEL assay (Gavrieli et al., 1992) . (In a pilot study not shown, comparable levels of apoptosis were observed in mice sacri®ced either 12, 24 or 48 h after treatment). Regardless of p53 genotype, doxorubicin caused a minimal induction of apoptosis in MMTV-ras tumors, which was not statistically signi®cant (P=0.24 for MMTV-ras/p53 +/+ tumors; P=0.08 for MMTV-ras/ p53 7/7 tumors) ( Figure 2 ). Thus, dierences in susceptibility to the induction of apoptosis did not account for the dierential response of MMTV-ras/ p53
+/+ and MMTV-ras/p53 7/7 tumors to doxorubicin. Similar results were obtained following a single paclitaxel treatment, with no signi®cant changes in apoptosis levels observed in mice of either genotype ( Figure 2 ). It should be noted that regardless of treatment, apoptosis levels in either the MMTV-ras/ p53 +/+ or MMTV-ras/p53 7/7 tumors were extremely low, corresponding to only a fraction of 1% of cells scoring as TUNEL-positive.
Eects of doxorubicin and paclitaxel on cell cycle pro®les of MMTV-ras/p53
+/+ and MMTV-ras/p53
salivary tumors p53 is capable of mediating either a G 1 arrest or apoptosis in response to DNA damage or other cellular perturbations (Yonish-Rouach, 1996) . Because there was no dierence in the induction of apoptosis by either agent in the MMTV-ras/p53
and MMTV-ras/p53 7/7 tumors, it was of interest to determine whether dierences in cell cycle eects accounted for the dierential response of the two tumor types to doxorubicin. Cell cycle distributions (G 0 /G 1 , S and G 2 /M fractions) were determined bȳ ow cytometric analysis for either untreated tumors or for tumors 48 h after a single treatment with doxorubicin or paclitaxel. Treatment of MMTV-ras/ p53 +/+ tumors with doxorubicin resulted in a signi®cant decrease in the S phase fraction, with a corresponding increase in G 1 (Figure 3a) , consistent with the induction of a p53-dependent G 1 checkpoint. In contrast, doxorubicin treatment of MMTV-ras/ +/+ and MMTV-ras/p53 7/7 mice. Tumor growth curves are shown for untreated (a, d), doxorubicin-treated (b, e) and paclitaxel-treated (c, f) salivary tumors arising in p53-wildtype (a,b,c) and p53-de®cient (d,e,f) MMTV-ras mice. Tumor-bearing mice were treated for nine consecutive days with doxorubicin or paclitaxel, and tumor growth was monitored daily by caliper measurements. Each line represents the growth of an individual tumor p53
7/7 tumors failed to cause an increase in G 1 , although a modest decrease in S phase was accompanied by an increase in the G 2 /M fraction ( Figure 3b ). This response is consistent with the loss of the p53-dependent G 1 checkpoint but activation of a secondary response resulting in a G 2 /M accumulation. Following treatment with paclitaxel, both classes of tumors underwent an increase in G 2 /M and corresponding decrease in S phase (Figure 3a,b) , and thus this response was largely p53-independent. The build-up of cells in G 2 /M is consistent with the known mechanism of action of paclitaxel, which perturbs microtubule function during mitosis (Rowinsky and Donehower, 1995) .
Mammary tumor growth response to doxorubicin and paclitaxel in MMTV-ras, MMTV-myc, and MMTV-ras/myc mice Numerous studies have indicated that doxorubicin induces p53-dependent apoptosis. Therefore, it was surprising to ®nd only a minimal induction of apoptosis following doxorubicin treatment of MMTV-ras/p53 +/+ tumors. However, we have previously demonstrated a dramatic induction of apoptosis in MMTV-ras tumors by a farnesyltransferase inhibitor, which functions at least in part by inhibiting Ras activity (Barrington et al., 1998) . Thus, we hypothesized that expression of activated ras in these tumors mediates a generalized resistance to apoptosis. In contrast, c-myc expression has been shown to greatly sensitize tumor cells to apoptotic stimuli (Evan et al., 1992; Klefstrom et al., 1997; Lotem and Sachs, 1993) , and we have previously demonstrated that MMTV-myc tumors exhibit much higher levels of spontaneous apoptosis than MMTVras tumors (Hundley et al., 1997a) . This raised the question of whether MMTV-myc tumors would be more sensitive to the induction of apoptosis in response to chemotherapy.
To address this question, similar doxorubicin and paclitaxel treatment experiments were conducted in tumor-bearing MMTV-myc and MMTV-ras/myc double-transgenic mice. Because these mice develop almost exclusively mammary tumors, we also treated mammary tumor-bearing MMTV-ras mice for comparison. As we have previously shown (Hundley et al., 1997a) , untreated tumors from the three transgenic genotypes displayed similar growth rates ( Figure  4a,d,g ). However, tumor response to daily administration of doxorubicin or paclitaxel for nine consecutive days diered depending on the transgenic genotype of the mouse. Treated tumors from MMTVmyc and MMTV-ras/myc mice exhibited a reduction in tumor size over the course of the doxorubicin treatment schedule, while tumors from the MMTV-ras mice displayed growth arrest but no reduction in tumor volume (Figure 4b,e,h ). Paclitaxel treatment resulted in similar growth responses in tumors of each of the dierent genotypes (Figure 4c,f,i) . Overall, tumors from MMTV-myc and MMTV-ras/myc mice responded signi®cantly better than tumors from 7/7 salivary tumors to doxorubicin and paclitaxel. TUNEL analysis was used to determine the levels of apoptosis in untreated and treated tumors of each genotype. TUNELpositive cells were identi®ed by light microscopy and quantitated as described in Materials and methods. The number of MMTVras/p53 +/+ tumors evaluated was: untreated, n=17; doxorubicintreated, n=6; paclitaxel-treated, n=6; MMTV-ras/p53 7/7 tumors: untreated, n=23; doxorubicin-treated, n=5; paclitaxeltreated, n=8 MMTV-ras mice to treatment with both doxorubicin and paclitaxel.
Apoptotic response of MMTV-ras, MMTV-myc and MMTV-ras/myc mammary tumors to doxorubicin and paclitaxel
To determine whether dierences in the induction of apoptosis accounted for the better tumor response in MMTV-myc and MMTV-ras/myc mice than in the MMTV-ras mice, TUNEL analysis was performed on each tumor type 48 h following treatment with doxorubicin or paclitaxel, and for untreated tumors, as above ( Figure 5 ). As reported previously (Hundley et al., 1997a) , untreated tumors from MMTV-ras, MMTV-myc, and MMTV-ras/myc mice exhibited markedly dierent spontaneous apoptosis levels. However, once again there were no statistically signi®cant changes in tumor apoptosis levels from mice of any of the genotypes following treatment with either doxorubicin or paclitaxel.
Eects of doxorubicin and paclitaxel on cell cycle pro®les in MMTV-ras, MMTV-myc, and MMTV-ras/ myc mammary tumors
As noted above for the MMTV-ras/p53
+/+ and MMTV-ras/p53 7/7 salivary tumors, the eects of both doxorubicin and paclitaxel on overall tumor growth for MMTV-ras, MMTV-myc, and MMTV-ras/myc mammary tumors could be largely accounted for by cell cycle changes (Figure 6 ). In all cases, treatment with doxorubicin resulted in an increase in the G 0 /G 1 fraction and a corresponding decrease in S phase fraction. In contrast, treatment with paclitaxel resulted in an accumulation of tumor cells in G 2 /M.
Discussion
Most preclinical chemotherapeutic drug evaluation is currently performed using tumor cells grown in culture or as mouse tumor xenografts. However, these models have a number of limitations, in part re¯ecting the unnatural tumor cell environment. Transgenic mouse tumor models oer new approaches for better understanding the eects of speci®c genetic alterations on overall tumor response and the mechanisms by which tumors can respond to dierent classes of agents within the context of naturally arising tumors in vivo.
Several transgenic mouse mammary/salivary tumor models have been generated by placing various oncogenes under the control of mouse mammary tumor virus (MMTV) transcriptional regulatory elements, or the promoter regions of other mammary gland-speci®c genes (Cardi and Muller, 1993) . These models are particularly amenable to drug evaluation studies since the tumors arise just beneath the skin and Figure 4 Mammary tumor growth response to doxorubicin and paclitaxel in MMTV-ras, MMTV-myc, and MMTV-ras/myc mice. Tumor growth curves for untreated and treated mammary tumors arising in MMTV-ras (a ± c), MMTV-myc (d ± f) and MMTV-ras/ myc (g ± i) mice are shown. Tumor-bearing mice were treated for nine consecutive days with doxorubicin or paclitaxel, and tumor growth was monitored daily by caliper measurements. Each line represents the growth of an individual tumor can be detected when they are quite small. It is therefore possible to obtain relatively accurate determinations of time of tumor onset and of rates of tumor growth. Two of the best characterized models are the MMTV-ras and MMTV-myc transgenic mice, both of which were originally created in the laboratory of Phil Leder (Cardi et al., 1991; Sinn et al., 1987; Stewart et al., 1984) . We have previously characterized tumors arising in these two classes of mice as well as in MMTV-ras/myc double transgenic mice (Hundley et al., 1997a) , and found that the dynamics of tumor growth varied markedly. While MMTV-ras tumors possess low levels of both proliferation and apoptosis, MMTV-myc tumors display signi®cantly higher levels Figure 5 Apoptotic response of MMTV-ras (a), MMTV-myc (b), and MMTV-ras/myc (c) mammary tumors to doxorubicin and paclitaxel. TUNEL analysis was used to determine the levels of apoptosis in untreated and treated tumors of each genotype. TUNEL-positive cells were identi®ed by light microscopy and quantitated as described in Materials and methods. The number of MMTV-ras tumors evaluated was: untreated, n=17, doxorubicin-treated, n=9; paclitaxel-treated, n=11; MMTV-myc tumors: untreated, n=10, doxorubicin-treated, n=8; paclitaxeltreated, n=8; MMTV-ras/myc tumors: untreated, n=14; doxorubicin-treated, n=10; paclitaxel-treated, n=14 Figure 6 Eects of doxorubicin and paclitaxel on cell cycle pro®les in MMTV-ras, MMTV-myc and MMTV-ras/myc mammary tumors. The relative fractions of cells in G 1 , S and G 2 /M phases of the cell cycle were determined using¯ow cytometric analysis of propidium iodide-stained mammary tumor cells from MMTV-ras (a), MMTV-myc (b) and MMTV-ras/myc (c) mice. The G 1 , S and G 2 /M phase fractions for untreated mammary tumors from MMTV-ras mice were 92.8+1.4, 4.2+0.7 and 3.4+0.8 (n=17), compared to 71.1+4.7, 23.7+4.7 and 5.2+0.5 for MMTV-myc (n=10) and 88.8+0.9, 8.5+0.8 and 2.7+0.2 for MMTV-ras/myc mice (n=14). The mean G 1 , S and G 2 /M phase fractions for doxorubicin-treated mammary tumors from MMTV-ras mice were 96.1+0.8, 1.9+0.4 and 1.9+0.5 (n=9), compared to 77.1+3.9, 15.3+3.2 and 7.5+1.2 for MMTV-myc (n=8) and 93.4+0.8, 3.3+0.6 and 3.2+0.6 for MMTV-ras/myc mice (n=10). The mean G 1 , S and G 2 /M phase fractions for paclitaxel-treated mammary tumors from MMTVras mice were 91.7+1.4, 2.9+0.4 and 4.9+1.2 (n=11), compared to 70.3+1.5, 18.4+1.0 and 11.3+1.0 for MMTV-myc (n=8) and 83.6+2.5, 9.6+1.8 and 6.8+0.9 for MMTV-ras/myc mice (n=10) of both, and MMTV-ras/myc tumors display intermediate levels.
Another well-characterized mouse tumor model is the p53-de®cient mouse created by targeted disruption of the p53 gene (Donehower et al., 1992) . These mice are highly tumor-prone, with most developing lymphomas or sarcomas by 6 months-of-age (Donehower et al., 1992; Jacks et al., 1994) . Although a variety of other tumor types are also observed at lower frequencies, mammary tumors are rare in these mice. Nevertheless, this model can be exploited to address the role of p53 in mammary tumorigenesis by interbreeding to one of the lines of mammary tumorprone transgenic mice (Cardi and Munn, 1995; Donehower et al., 1995) . We previously interbred the p53 knock-out mice to MMTV-ras mice, and found that p53 de®ciency resulted in accelerated salivary but not mammary tumorigenesis. While p53-de®cient tumors displayed higher genomic instability and S phase fractions than p53-wildtype tumors, they were nearly identical with regard to apoptosis levels (Hundley et al., 1997b) .
It is of particular interest to determine how various genetic alterations aect tumor sensitivity to dierent classes of chemotherapeutic agents. Doxorubicin and paclitaxel are among the most eective and widely used chemotherapeutic agents for a number of human cancers (Dorr and Von Ho, 1994) . These agents were selected for this study because of their distinct mechanisms of action and dierences in relative dependence on p53 function for tumor response. Treatment with doxorubicin leads to DNA double strand breaks through inhibition of DNA topoisomerase II (Tewey et al., 1984) . However, an additional proposed mechanism of action involves the formation of oxygen free radical intermediates that cause a variety of cytotoxic eects, including DNA strand scission and lipid peroxidation (Dorr and Von Ho, 1994 ). An early cellular response to doxorubicin is the induction of the p53-dependent G 1 -arrest cell cycle checkpoint (Nelson and Kastan, 1994) . In contrast, paclitaxel functions as a mitotic spindle poison by inhibiting microtubule depolymerization (Dorr and Von Ho, 1994; Manfredi and Horwitz, 1984) . The major cell cycle response to paclitaxel is therefore the accumulation of cells in G 2 /M, and this arrest is largely p53-independent (Wahl et al., 1996) . In addition to their cell cycle eects, both doxorubicin and paclitaxel are potent inducers of apoptosis (Bhalla et al., 1993; Milas et al., 1995; Skladanowski and Konopa, 1993) . Thus, the relative contributions of cell cycle arrest and induction of apoptosis to the overall tumor response to treatment with doxorubicin and paclitaxel were evaluated in this study.
We expected that p53-de®cient MMTV-ras tumors would respond less eciently than p53-wildtype MMTV-ras tumors to doxorubicin, but that both tumor types would respond to paclitaxel, and as shown in Figure 1 , this was indeed the case. Interestingly, the tumor growth responses could be accounted for in large part by changes in cell cycle distribution. p53-wildtype tumors underwent immediate growth arrest in response to doxorubicin, corresponding to increased G 1 and decreased S phase fractions. In contrast, p53-de®cient tumors were impaired in their ability to growth arrest, and this correlated with a failure to undergo G 1 arrest. However, following paclitaxel treatment, both tumor types displayed an immediate growth arrest accompanied by an accumulation of cells in G 2 /M.
The role of p53 in mediating tumor response to chemotherapeutic treatment has been attributed in large part to the ability of p53 to induce apoptosis (Fisher, 1994; Kerr et al., 1994; Lowe et al., 1993) . It was therefore surprising that neither agent signi®cantly induced apoptosis in MMTV-ras mice, regardless of p53 status. One potential explanation for the lack of an apoptotic response to doxorubicin and paclitaxel treatment in these tumors is that one or more Ras signaling pathways mediate resistance to apoptosis. Indeed, numerous studies have demonstrated that ras can promote increased resistance to a variety of apoptotic stimuli (Arends et al., 1993; Hundley et al., 1997a; Kaumann-Zeh et al., 1997; Lin et al., 1995; Nooter et al., 1995) . Further, we have shown that treatment of tumor-bearing MMTV-ras mice with an inhibitor of Ras function results in a dramatic induction of apoptosis (Barrington et al., 1998) .
To determine whether doxorubicin and paclitaxel could induce apoptosis more eciently in tumor types displaying a higher intrinsic apoptotic potential, we compared the drug responses of mammary tumors from MMTV-myc and MMTV-ras/myc mice to those from MMTV-ras mice. The myc and ras/myc tumors did in fact respond more eciently, since both underwent marked tumor regression in response to either agent, as compared to the tumor growth arrest seen in ras tumors. Once again, though, the responses were not attributable to drug-induced apoptosis, but to changes in cell cycle distribution. These results therefore demonstrate that even in the absence of an elevation of apoptosis following chemotherapy, drug-induced cell cycle arrest can cooperate with high spontaneous apoptosis levels to induce tumor regression.
Most anticancer agents function by inducing either cell cycle arrest, apoptosis, or both. However, the ability of tumor cells to undergo either response is strongly in¯uenced by their combination of genetic alterations in oncogenes and tumor suppressor genes, as well as in numerous other classes of genes, such as DNA damage repair genes or drug metabolism genes. Transgenic mouse tumor models oer a means for introducing well-de®ned genetic alterations, either alone or in combination, to assess their eects on a variety of tumor properties. Moreover, they provide relatively accurate in vivo models for evaluating the eects of speci®c genetic alterations on overall tumor growth response to chemotherapeutic agents, and on the mechanisms by which tumors may respond. These studies suggest that genetically engineered mice are a powerful tool for dissecting tumor genotype/phenotype correlations and may be a useful complement to cell culture and xenograft models for chemotherapeutic drug evaluation.
Materials and methods

Mice p53
7/7 mice were obtained from GenPharm International, and a breeding license was obtained from Taconic to permit the interbreeding of these mice to other lines of mice. MMTV-ras and MMTV-myc mice were obtained from Charles River Laboratories, and a breeding license from EI DuPont de Nemours and Co. was acquired to authorize the interbreeding of these mice. The p53 7/7 mice were originally obtained in a C57BL/6 background, while the MMTV-ras and MMTV-myc mice were obtained in an FVB background. However, they were subsequently maintained in our laboratory in a mixed genetic background including C57BL/6, FVB, and Balb/c. The presence or absence of the transgenes and p53 alleles in ospring of the various interbreedings was determined by PCR. Genomic DNA was extracted from a small piece of tail cut from each animal at the time of weaning. PCR reactions utilizing three primers allowed for detection of both wildtype and knockout p53 alleles in a single reaction. The primers used consisted of a sense 5' primer speci®c for exon 4 (5'-GGGACAGCCAAGTCTGTTATGTGC-3') and two antisense 3' primers speci®c for either exon 6 of p53 (5'-CTGTCTTCCAGATACTCGGGATAC-3') for detection of the wildtype allele, or the neo cassette (5'-TTTACG-GAGCCCTGGCGCTCGATGT-3') for detection of the knock-out allele. The PCR reaction was run for 35 cycles of 948C for 1 min, 608C for 1 min, and 728C for 1 min. The primers used for the detection of the MMTV-ras transgene were 5'-CCCAAGGCTTAAGTAAGTTTTTGG-3' (5' sense primer) and 5'-GGGCATAAGCACAGATAAAACACT-3' (3' antisense primer). Primers used for the detection of the MMTV-myc transgene were: 5'-GGTGATAGTCCCTTCA-CATC-3' (5' sense primer) and 5'-GTGCCACCTGACGTC-TAAGA-3 (3' antisense primer). Both reactions were run for 35 cycles of 948C for 1 min, 588C for 1 min and 728C for 1 min.
Drug treatment of tumor-bearing mice
Animals were checked twice weekly, either visually or by palpation, for the presence of tumors. Once a tumor was detected, tumor growth was monitored by taking caliper measurements until a volume of 200 ± 1000 mm 3 was attained. Tumor volume was calculated according to the formula: tumor volume (mm 3 )=(W 2 6L)/2 where W=tumor width and L=tumor length in millimeters. The maximum tolerated doses (MTDs) for doxorubicin (Cetus Oncology, Emeryville, CA, USA) and paclitaxel (Bristol Myers Squibb, Princeton, NJ, USA) were determined previously for both single and multiple injection schedules (personal communication, G Mangold). For tumor growth studies, doxorubicin or paclitaxel were administered intraperitoneally at their multiple injection MTDs (2 mg/kg or 15 mg/kg, respectively) once daily for 9 days, and tumor growth was monitored by taking daily caliper measurements. Tumor mean growth rates (MGRs) were determined by performing linear regression analysis on each tumor growth curve; the slopes of the lines for each genotype were then determined and averaged to yield MGR values. Comparisons of tumor MGRs between mice of dierent genotypes were tested for statistical signi®cance using the Mann-Whitney U-test. For the measurement of apoptosis and cell cycle parameters, a single injection of the MTD for each agent (10 mg/kg doxorubicin or 20 mg/kg paclitaxel) was administered, and the animals were sacri®ced 48 h later. All matings and maintenance of mice were conducted as previously described (Hundley et al., 1997a,b) .
Apoptosis analysis
Tumor samples were collected and ®xed in 10% buered formalin (pH 7). The samples were then processed and embedded in paran. The TUNEL method was used to label apoptotic cells in situ (Gavrieli et al., 1992) , and sections were evaluated by light microscopy. Positively labeled cells within a 10610 mm grid in the eyepiece were counted in ten 4506 ®elds. Staining in areas of the tumor that were necrotic by light microscopy were avoided. The apoptotic cells in non-necrotic regions of tumors appeared in most cases to be uniformly distributed throughout viable regions of the tumor. The total number of tumor cells in each ®eld ranged from 500 ± 800, depending on the histological pattern of the tumor. Per cent apoptosis was calculated based on an average of 670 cells per ®eld. Statistical signi®cance of dierences between groups was evaluated using a Student t-test.
Flow cytometry
Upon sacri®cing a tumor-bearing mouse, a 25 ± 50 mg piece of tumor tissue was frozen in liquid nitrogen, and stored at 7808C until the time of analysis. Tissue was processed, stained with propidium iodide, and then analysed with an EPICS ELITE¯ow cytometer (Coulter Cytometry, Miami, FL, USA) as previously described (Hundley et al., 1997a) . Histograms were analysed for cell cycle compartments using MultiCycle-PLUS Version 3.0 (Phoenix Flow Systems, San Diego, CA, USA). A minimum of 50 K events were collected in order to maximize statistical validity of the compartmental analysis. Dierences in G1 and S phase fractions between groups were evaluated using a Student t-test.
